Trojan, Lutz

[["dc.bibliographiccitation.firstpage","1293"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","European Radiology"],["dc.bibliographiccitation.lastpage","1307"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Rücker, Gerta"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2019-08-05T10:33:02Z"],["dc.date.available","2019-08-05T10:33:02Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose To compare partial nephrectomy (PN), radiofrequency ablation (RFA), cryoablation (CRA) and microwave ablation (MWA) regarding oncologic, perioperative and functional outcomes. Material and methods The MEDLINE, EMBASE and COCHRANE libraries were searched for studies comparing PN, RFA, CRA or MWA and reporting on any-cause or cancer-specific mortality, local recurrence, complications or renal function. Network meta-analyses were performed. Results Forty-seven studies with 24,077 patients were included. Patients receiving RFA, CRA or MWA were older and had more comorbidities compared with PN. All-cause mortality was higher for CRA and RFA compared with PN (incidence rate ratio IRR = 2.58, IRR = 2.58, p < 0.001, respectively). No significant differences in cancer-specific mortality were evident. Local recurrence was higher for CRA, RFA and MWA compared with PN (IRR = 4.13, IRR = 1.79, IRR = 2.52, p < 0.05 respectively). A decline in renal function was less pronounced after RFA versus PN, CRA and MWA (mean difference in GFR MD = 6.49; MD = 5.82; MD = 10.89, p < 0.05 respectively). Conclusion Higher overall survival and local control of PN compared with ablative therapies did not translate into significantly better cancer-specific mortality. Most studies carried a high risk of bias by selecting younger and healthier patients for PN, which may drive superior survival and local control. Physicians should be aware of the lack of high-quality evidence and the potential benefits of ablative techniques for certain patients, including a superior complication profile and renal function preservation. Key Points • Patients selected for ablation of small renal masses are older and have more comorbidities compared with those undergoing partial nephrectomy. • Partial nephrectomy yields lower all-cause mortality, which is probably biased by patient selection and does not translate into prolonged cancer-free survival. • The decline of renal function is smallest after radiofrequency ablation for small renal masses."],["dc.identifier.doi","10.1007/s00330-018-5660-3"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/62282"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.relation.issn","0938-7994"],["dc.relation.issn","1432-1084"],["dc.title","Partial nephrectomy versus ablative techniques for small renal masses: a systematic review and network meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3010"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Cancers"],["dc.bibliographiccitation.volume","12"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Delonge, Laura M."],["dc.contributor.author","Haack, Anna-Maria"],["dc.contributor.author","Shuch, Brian"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Bremmer, Felix"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2021-04-14T08:31:08Z"],["dc.date.available","2021-04-14T08:31:08Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.3390/cancers12103010"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17620"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/83497"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.publisher","MDPI"],["dc.relation.eissn","2072-6694"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Radiomic Features and Machine Learning for the Discrimination of Renal Tumor Histological Subtypes: A Pragmatic Study Using Clinical-Routine Computed Tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","924"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","European Urology Focus"],["dc.bibliographiccitation.lastpage","936"],["dc.bibliographiccitation.volume","4"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T14:23:51Z"],["dc.date.available","2020-12-10T14:23:51Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.euf.2017.08.007"],["dc.identifier.issn","2405-4569"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72062"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Gender-specific Differences in Recurrence of Non–muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","122"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","The Open Public Health Journal"],["dc.bibliographiccitation.lastpage","133"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Hosseini, Ali Seif Amir"],["dc.date.accessioned","2019-07-09T11:45:23Z"],["dc.date.available","2019-07-09T11:45:23Z"],["dc.date.issued","2018"],["dc.description.abstract","Purpose: To summarize the current evidence on preventive services utilization in cancer survivors. Methods: A systematic literature review and meta-analysis was conducted in February 2016. Studies were included if they compared the utilization of influenza vaccination, cholesterol/lipid testing, bone densitometry, or blood pressure measurement among survivors of adulthood cancer to cancer-free controls. Random effects meta-analyses were conducted to pool estimates. Results: Literature search identified 3740 studies of which 10 fulfilled the inclusion criteria. Cancer survivors were significantly more likely to utilize bone densitometry (OR=1.226, 95% CI: 1.114 – 1.350, p<0.001) and influenza vaccination (OR=1.565, 95% CI: 1.176 – 2.082, p=0.002) than cancer-free controls. No statistically significant differences were detected for blood pressure measurement and cholesterol/lipid testing (OR=1.322, 95% CI: 0.812 – 2.151, p=0.261; OR=1.046, 95% CI: 0.96 – 1.139, p=0.304). Conclusions: Cancer survivors were more likely to receive influenza vaccinations and bone densitometry. Future studies should evaluate underlying mechanisms and whether the utilization of preventive services translates into prolonged survival of cancer survivors. Implications for Cancer Survivors: Our meta-analysis demonstrated cancer survivors to be more likely to receive the preventive services such as influenza vaccination and bone densitometry than cancer free controls. Still, these results should be interpreted in the context of suboptimal utilization of preventive services in general, and for cancer survivors in specific. Future research should evaluate the underlying mechanisms and whether utilization of preventive services is associated with overall survival in cancer survivors."],["dc.identifier.doi","10.2174/1874944501811010122"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/15190"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/59219"],["dc.language.iso","en"],["dc.notes.intern","Merged from goescholar"],["dc.relation.issn","1874-9445"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.subject.ddc","610"],["dc.title","Preventive Services Utilization Among Cancer Survivors Compared to Cancer-free Controls"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","48"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Urology"],["dc.bibliographiccitation.lastpage","60"],["dc.bibliographiccitation.volume","200"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Seif Amir Hosseini, Ali"],["dc.contributor.author","Simon, Jörg"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Schmid, Marianne"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T15:20:08Z"],["dc.date.available","2020-12-10T15:20:08Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/j.juro.2017.11.150"],["dc.identifier.eissn","1527-3792"],["dc.identifier.issn","0022-5347"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72566"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Gender Specific Differences in Disease-Free, Cancer Specific and Overall Survival after Radical Cystectomy for Bladder Cancer: A Systematic Review and Meta-Analysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","277"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","CardioVascular and Interventional Radiology"],["dc.bibliographiccitation.lastpage","283"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Uhlig, Annemarie"],["dc.contributor.author","Hahn, Oliver"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Müller-Wille, René"],["dc.contributor.author","Uhlig, Johannes"],["dc.date.accessioned","2020-12-10T14:10:01Z"],["dc.date.available","2020-12-10T14:10:01Z"],["dc.date.issued","2017"],["dc.identifier.doi","10.1007/s00270-017-1816-9"],["dc.identifier.eissn","1432-086X"],["dc.identifier.issn","0174-1551"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70640"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Treatment for Localized T1a Clear Cell Renal Cell Carcinoma: Survival Benefit for Cryosurgery and Thermal Ablation Compared to Deferred Therapy"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e19725"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Biggemann, Lorenz"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Kim, Hyun S."],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2021-04-14T08:26:39Z"],["dc.date.available","2021-04-14T08:26:39Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1097/MD.0000000000019725"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17378"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/82031"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","1536-5964"],["dc.relation.issn","0025-7974"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Discriminating malignant and benign clinical T1 renal masses on computed tomography"],["dc.title.alternative","A pragmatic radiomics and machine learning approach"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","e15346"],["dc.bibliographiccitation.issue","17"],["dc.bibliographiccitation.journal","Medicine"],["dc.bibliographiccitation.volume","98"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Uhlig, Johannes"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Uhlig, Annemarie"],["dc.date.accessioned","2020-12-10T18:20:07Z"],["dc.date.available","2020-12-10T18:20:07Z"],["dc.date.issued","2019"],["dc.description.abstract","To assess whether left and right-sided renal cell carcinoma (RCC) carry side-specific outcomes.Surgically treated RCC patients were included from the United States Surveillance, Epidemiology and End Results database (Surveillance, Epidemiology and End Results database [SEER]; 2013 version) and the German Centre for Cancer Registry Data (ZfKD; 2000-2014). Bilateral RCC, those with missing RCC staging, follow-up time, and survival status were excluded. Cancer-specific survival (CSS) according to RCC side was compared using multivariable Cox regression.Seventeen thousand seven hundred nine SEER patients and 41,967 ZfKD patients were included. In both datasets, patients with left-sided RCC had higher T status and more often presented with nodal positive or metastatic disease. In the SEER dataset 1258 (14.33%) patients with left-sided RCC underwent lymphadenectomy (LAD), compared to 908 (10.17%) LADs in right-sided RCC (P <.001). CSS was inferior for left-sided in both datasets after multivariable adjustment (SEER HR = 1.187, 95% CI 1.048-1.345, P = .007, P = .008; ZfKD HR = 1.155, 95% CI 1.046-1.275, P = .004).In the SEER population, site-specific CSS differences were driven by whether or not a LAD was performed. Among SEER patients with LAD no statistically significant differences in laterality were observed (HR 1.096, 95% CI 0.8977-1.337, P = .396) whereas, in absence of LAD, CSS was shorter for individuals with left-sided tumor (HR = 1.176, 95%CI 1.002-1.38, P = .0468).Although the overall survival difference was only marginal, left-sided RCC in surgically treated patients tends to present at more advanced stage and has in general worse CSS, especially in patients without LAD. Site-specific lymphogenic spread patterns might contribute to these findings. Further prospective studies should evaluate, whether side-adapted LAD protocols influence outcomes in RCC patients."],["dc.description.sponsorship","Open-Access-Publikationsfonds 2019"],["dc.identifier.doi","10.1097/MD.0000000000015346"],["dc.identifier.issn","0025-7974"],["dc.identifier.pmid","31027111"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16077"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/75460"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.notes.intern","In goescholar not merged with http://resolver.sub.uni-goettingen.de/purl?gs-1/16329 but duplicate"],["dc.notes.status","final"],["dc.relation.eissn","1536-5964"],["dc.relation.haserratum","/handle/2/110673"],["dc.relation.issn","0025-7974"],["dc.rights","CC BY-NC-ND 4.0"],["dc.rights.access","openAccess"],["dc.rights.uri","https://creativecommons.org/licenses/by-nc-nd/4.0"],["dc.subject.ddc","610"],["dc.title","Tumor laterality in renal cancer as a predictor of survival in large patient cohorts: A STROBE compliant study"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1934"],["dc.bibliographiccitation.issue","16"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","1940"],["dc.bibliographiccitation.volume","75"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Strauss, A."],["dc.contributor.author","Meller, J."],["dc.contributor.author","Ritter, Christian Oliver"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Schildhaus, H.-U."],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.date.accessioned","2018-11-07T09:48:43Z"],["dc.date.available","2018-11-07T09:48:43Z"],["dc.date.issued","2015"],["dc.description.abstract","BACKGROUNDThe first evaluation of pelvic extended lymph node dissection (pLND) in oligometastatic prostate cancer (PCa) detected by Ga-68-PSMA PET/CT. METHODSRetrospective analysis of 35 PCa patients underwent Ga-68-PSMA PET/CT affected by biochemical recurrence (BCR) after curative treatment (n=23) or before primary therapy of high-risk PCa (n=12). We performed pLND associated with pathologic imaging in 17 men with nodal oligometastatic PCa. RESULTSIndicative lesions for PCa in PET/CT were detected in 91.4% (32 of 35) of patients. Nodal, bone, visceral (pulmonary), and within the prostate suspected disease were detected in 72% (23 of 32), 16% (5 of 32), 6% (2 of 32), and 47% (15 of 32) of patients, respectively. Median serum PSA in patients with pathological radiotracer uptake in recurrent and high-risk PCa patients was 2.9ng/ml (range 0.18-30) and 19.5ng/ml (range 6-90), respectively. The median number of removed lymph nodes with pLND in recurrent and high-risk PCa was 10 (range 4-17) and 12 (range 8-29) per patient and the median number of positive lymph nodes was 1 (range 1-2) and 3 (2-3) per patient, respectively. In total, two false positive and one false-negative lymph node were found. Diagnostic accuracies per nodal lesion in total of 213 removed nodes: sensitivity, 94%; specificity, 99%; positive predictive value (PPV), 89%, and negative predictive value (NPV), 99.5%. After pLND, 53% (9 of 17) of patients received androgen deprivation therapy and/or radiation therapy and hormonal therapy, while 47% (8 of 17) of patients remained free of any post-surgery therapy. Follow-up PSA remained less than 0.2ng/ml in 82% (14 of 17) of patients. After pLND, immediate BCR (PSA never measured less than 0.2ng/ml) in 18% (3 of 17) of patients was recorded. CONCLUSIONSThis represents the first study of pLND in the setting of nodal oligometastatic PCa detected by Ga-68-PSMA PET/CT. The use of Ga-68-PSMA PET/CT could be to improve the accuracy for the detection of nodal micrometastases. These promising findings need validation in larger studies. Prostate 75:1934-1940, 2015. (c) 2015 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/pros.23091"],["dc.identifier.isi","000363219300013"],["dc.identifier.pmid","26356236"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35365"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","Pelvic lymph node dissection for nodal oligometastatic prostate cancer detected by Ga-68-PSMA-positron emission tomography/computerized tomography"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","776"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","The Prostate"],["dc.bibliographiccitation.lastpage","780"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Hijazi, Sameh"],["dc.contributor.author","Meller, Birgit"],["dc.contributor.author","Leitsmann, Conrad"],["dc.contributor.author","Strauss, Arne"],["dc.contributor.author","Ritter, Christian"],["dc.contributor.author","Lotz, Joachim"],["dc.contributor.author","Meller, Johannis"],["dc.contributor.author","Trojan, Lutz"],["dc.contributor.author","Sahlmann, Carsten-Oliver"],["dc.date.accessioned","2018-11-07T10:14:00Z"],["dc.date.available","2018-11-07T10:14:00Z"],["dc.date.issued","2016"],["dc.description.abstract","BACKGROUNDOur study is the first evaluation of nodal metastatic prostate cancer (PCa) to mesorectal lymph nodes (MLN) detected by Ga-68-PSMA-PET/CT. METHODSWe retrospectively analyzed 76 consecutive PCa patients who underwent Ga-68-PSMA-PET/CT: 61 PCa patients with biochemical recurrence (BCR) after curative treatment and 15 high-risk PCa before primary therapy. We assessed PET-positive MLN, which are indicative for PCa. RESULTSWe detected PET-positive lesions for PCa in Ga-68-PSMA-PET/CT in 66 of 76 (87%) patients. Nodal disease was imaged in 47 of 66 (71%) patients. Indicative mesorectal nodal lesions for PCa were detected in 12 of 76 (15.8%) patients. The median number of PET-positive MLN was one per patient. Seven of twelve patients had recurrent PCa after radical prostatectomy with a median PSA value of 1.84ng/ml (range 0.31-13). Five of twelve patients had untreated first diagnosed high-risk PCa with median PSA value of 90ng/ml (range 4.6-93) at PET/CT, respectively. For all PET positive MLN a morphological correlate was found in CT (shortest diameter median 4mm [range 4-21]; longest diameter median 7.5mm [range 5-25]). After PET/CT, four patients with recurrent PCa received hormonal therapy, one patient was treated with directed radiation therapy of MLN, one patient received chemotherapy, and one patient was treated with pelvic lymph node dissection. Three high-risk PCa patients received hormonal therapy, and two patients were treated with adjuvant hormonal therapy after radical prostatectomy. CONCLUSIONSDetection and exact location of nodal metastasis for PCa is crucial for the choice of treatment and the patient's prognosis. Ga-68-PSMA-PET/CT seems to improve the detection of nodal metastasis in PCa, especially concerning mesorectal lymph nodes. Prostate 76:776-780, 2016. (c) 2016 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/pros.23168"],["dc.identifier.isi","000374860200008"],["dc.identifier.pmid","26880517"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/40540"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1097-0045"],["dc.relation.issn","0270-4137"],["dc.title","See the unseen: Mesorectal lymph node metastases in prostate cancer"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]